Ixekizumab for treatment of psoriasis.
Psoriasis is a prevalent chronic inflammatory skin disease of unknown etiology. Recent advances in understanding the pathogenesis of psoriasis suggest that IL-17 is a key proinflammatory mediator present in the skin. Several agents targeting IL-17 or its receptor are in clinical trials for the treatment of psoriasis. This review focuses on the biological rationale and the results of clinical trials with ixekizumab, a humanized IgG4 monoclonal antibody. Ixekizumab binds the IL-17A homodimer, thereby blocking the binding of IL-17A to the IL-17 receptor. The currently available Phase I-III data indicate that ixekizumab is a promising drug, although long-term data of efficacy and safety are needed before ixekizumab and other IL-17 targeting therapeutics can find their place in clinical practice.
Department of Dermato-Allergology, Gentofte Hospital, University of Copenhagen, Kildegaardsvej 28, DK-2900 Hellerup, Denmark.
Beatrice
B
Dyring-Andersen
Lone
L
Skov
Claus
C
Zachariae
D000818:Animals; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D020381:Interleukin-17 / Q000276:immunology / Q000378:metabolism*; D058990:Molecular Targeted Therapy; D011485:Protein Binding / Q000187:drug effects; D011565:Psoriasis / Q000188:drug therapy* / Q000276:immunology; D053722:Receptors, Interleukin-17 / Q000037:antagonists & inhibitors*; D012867:Skin / Q000187:drug effects* / Q000276:immunology
D061067:Antibodies, Monoclonal, Humanized; D020381:Interleukin-17; D053722:Receptors, Interleukin-17; C549079:ixekizumab
IL-17A; IL-17F; IL-22; ixekinumab; psoriasis